Key result
Full implementation of dapagliflozin in eligible patients with acute heart failure would yield a 1-year absolute risk reduction of 2.3% for death (NNT=43) and 5.7% for HF rehospitalization (NNT=17).
Why the study?
The study was conducted to determine the projected benefits of dapagliflozin after an acute heart failure event in Spain.
Does full implementation of dapagliflozin reduce death and heart failure rehospitalization in patients aged ≥50 years admitted with acute heart failure?
Cohort (n=5,644)
Yes
Does full implementation of dapagliflozin reduce death and heart failure rehospitalization in patients aged ≥50 years admitted with acute heart failure?
Full implementation of dapagliflozin in real-world patients admitted with acute heart failure could significantly reduce 1-year mortality and rehospitalization burden.
Answers are grounded in this paper and cite their sources.
May support broad dapagliflozin use post-acute HF; extends trial eligibility data to Spanish cohorts but leaves practice change open.
Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF) event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 years or older consecutively admitted with HF to internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were calculated via pooled analysis of the DAPA-HF and DELIVER trials. Results: A total of 5644 subjects were analyzed, of whom 79.2% were eligible for dapagliflozin, according to criteria of the DAPA-HF and DELIVER trials. Full implementation of dapagliflozin would imply a 1-year absolute risk reduction of 2.3% for death (number needed to treat = 43) and 5.7% (number needed to treat = 17) for HF rehospitalization. Conclusion: Treatment with dapagliflozin could significantly reduce HF burden in clinical practice.
No takes yet. Share an insight, caveat, or question.
Montero-Pérez-Barquero et al. (2023) conducted a cohort in acute heart failure (n=5,644). Dapagliflozin was evaluated on death (ARR 2.3%). Full implementation of dapagliflozin in eligible patients with acute heart failure would yield a 1-year absolute risk reduction of 2.3% for death (NNT=43) and 5.7% for HF rehospitalization (NNT=17).
Synapse has enriched 10 related papers. Consider them for comparative context: